NCT07299500 Study of a Cohort of Non-HIV Immunocompromised Patients With Toxoplasmosis at the Strasbourg University Hospital
| NCT ID | NCT07299500 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Hospital, Strasbourg, France |
| Condition | Cerebral Toxoplasmosis |
| Study Type | OBSERVATIONAL |
| Enrollment | 30 participants |
| Start Date | 2025-02-02 |
| Primary Completion | 2026-02 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 30 participants in total. It began in 2025-02-02 with a primary completion date of 2026-02.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Toxoplasmosis in HIV-positive individuals is well-studied and has a codified management protocol, which is not the case for other immunodeficiencies, except for recent recommendations in the context of hematopoietic stem cell transplantation. A description of this population is necessary to estimate the number of patients affected and to define their specific management (diagnosis, treatment, prevention).
Eligibility Criteria
Inclusion Criteria: * Adult (≥18 years) * Immunocompromised (i.e., solid organ transplant recipient, hematological malignancy, cancer patient, patient treated with immunosuppressive therapy or therapy affecting the immune system by any mechanism, hematopoietic stem cell transplant recipient, patient with an autoimmune disease or immunodeficiency, whether primary or secondary). * At least one positive toxoplasmosis PCR test (regardless of tissue) Exclusion Criteria: * Subject who has expressed opposition to the reuse of their data for scientific research. * HIV positive * Congenital toxoplasmosis * Isolated ocular toxoplasmosis in immunocompetent individuals
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07299500 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Cerebral Toxoplasmosis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07299500 currently recruiting?
Yes, NCT07299500 is actively recruiting participants. Contact the research team at mathilde.herber@chru-strasbourg.fr for enrollment information.
Where is the NCT07299500 trial being conducted?
This trial is being conducted at Strasbourg, France.
Who is sponsoring the NCT07299500 clinical trial?
NCT07299500 is sponsored by University Hospital, Strasbourg, France. The trial plans to enroll 30 participants.